PARIS—Sanofi SA said Monday it would buy Belgian biotech Ablynx NV for €3.9 billion ($4.85 billion), the French drugmaker’s second acquisition this month after purchasing U.S. hemophilia specialist Bioverativ Inc.
Sanofi will pay €45 a share for Ablynx, which earlier this month rejected a €2.6 billion offer from Denmark’s Novo Nordisk A/S. Novo Nordisk said Monday it won’t be making a revised proposal.
The... To Read the Full Story Subscribe Sign In